We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Following the June update that allowed for a lower dose ...

Postexposure prophylaxis with bamlanivimab plus etesevimab is not a substitute for vaccination against COVID-19. The Food and Drug Administration (FDA) has expanded the Emergency Use Authorization ...

In a study conducted at the University of Washington, USA, the researchers assert that post-exposure prophylaxis with monoclonal antibodies could improve the clinical outcomes and health system costs ...

In a recent study posted to the medRxiv* preprint server, researchers determined evidence for post-exposure vaccination in reducing the mortality rate of coronavirus disease 2019 (COVID-19).

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A single subcutaneous dose of Regeneron’s antibody ...

Ensitrelavir significantly reduced the likelihood of developing symptomatic COVID-19 following household exposure compared with placebo. Treatment with ensitrelvir was found to prevent symptomatic ...

Heavy is the head that wears the COVID-19 crown. Late last week, Pfizer revealed its antiviral Paxlovid fell short in a post-exposure protection trial. Still, in the pill’s quest to reach as many ...

OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) delivered a late-breaking scientific oral ...